Feature | June 10, 2007 | Cristen C. Bolan

A Fair Playing Field in Digital Mammography?

In a recent letter to the editor, an ITN reader brought up the decision made on May 23rd, 2006, to re-classify digital mammography from a Class III product to Class II. According to the reader, “This was widely thought to mean that the complicated and lengthy process of filing a PMA to gain FDA approval to market digital mammography would no longer be required.”
It was thought that the benefits of the proposed re-classification would enable a much simpler 510(k) application to FDA to be used to gain clearance to market digital mammography. In the meeting, Robert Jennings, M.D., of the FDA said: “The big difference which we feel goes a long way towards our goal of least burdensome approach to device clearance is that we will use, instead of a large clinical trial, simply reader evaluation of clinical films as is done in the ACR accreditation process.”
This would allow manufacturers entering the market to avoid the lengthy clinical study required in the PMA process. The new approach would also benefit patient care by not double exposing participants.
Although it was unanimously recommended that the FDA should develop the guidance documents required to reclassify digital mammography to a 510(k), nine months later, the FDA stated that it would take at least an additional one and a half to two years for the FDA to complete the guidance documents describing the requirements for a digital mammography 510(k). They added that the ultimate requirements would include a large clinical trial similar to that required for a PMA, including double exposure of participating patients and a one-year follow-up of negative diagnoses.
Why did the reader bring this to my attention? In hopes that other industry experts would join in on requesting that the FDA complete “the guidance documents for digital mammography 510(k) within the next six months” and “eliminate the need for a large clinical trial for a digital mammography 510(k).” This way, our reader believes, other qualified manufacturers would not be left sitting on the sidelines, while just a few players “divide up the large and growing digital mammography market.”
It begs the question – has the FDA established a fair playing field for all qualified manufacturers or does the market cater to a few powerhouses to lead the medical imaging market? That’s for you to decide. I just hope, above all, it’s catering to the patients.

We welcome your comments on the topics found in Imaging Technology News.
Please send your thoughts to [email protected]
Please send press releases to [email protected]
and chart responses to [email protected]

Related Content

Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
Ikonopedia Introduces Automated Combined Reporting Package at SBI
News | Mammography Reporting Software | April 04, 2019
Ikonopedia will introduce its new Automated Combined Reporting package at the 2019 Society of Breast Imaging/American...
Konica Minolta Highlights New Exa Mammo Features at SBI/ACR Breast Imaging Symposium
News | Breast Imaging | April 03, 2019
Konica Minolta Healthcare Americas Inc. will highlight new features of Exa Mammo, a picture archiving and communication...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Lunit Showcases AI Solution for Breast Cancer at SBI 2019
News | Artificial Intelligence | April 02, 2019
Medical artificial intelligence (AI) startup Lunit announced its attendance at the Society of Breast Imaging (SBI) 2019...